Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 2/20 | 0.56 |
| ▸ | ATP4B | P51164 | 2/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | C1S | P09871 | 1/20 | 0.51 |
| ▸ | VCP | P55072 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11239265 | 0.85 | MAPT (0.57) | RAB9AMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3602570 | 0.85 | ABL1 (0.67) | ATP4AATP4BRAB9AHTTABL1 | |
| SCHEMBL2393684 | 0.85 | HDAC3 (0.59) | RAB9AMAPTMEN1KMT2AHTT | |
| SCHEMBL3615155 | 0.85 | ALOX5 (0.51) | ATP4AATP4BRAB9AMAPTMEN1 | |
| SCHEMBL11090239 | 0.85 | MAPT (0.51) | RAB9AMAPTMEN1KMT2AHTT | |
| SCHEMBL3608636 | 0.84 | MAPT (0.51) | RAB9AMAPTMEN1KMT2AHTT | |
| Hydrochloric Acid SCHEMBL11254127 | 0.84 | HDAC3 (0.60) | ATP4AATP4BRAB9AMAPTMEN1 | |
| Bromide SCHEMBL7141567 | 0.84 | HDAC3 (0.58) | ATP4AATP4BRAB9AMAPTMEN1 | |
| SCHEMBL3606891 | 0.84 | ABL1 (0.68) | ATP4AATP4BMAPTMEN1KMT2A | |
| SCHEMBL28484317 | 0.84 | MEN1 (0.58) | MAPTMEN1KMT2AMAPK1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| CN-111825633-B | Method for synthesizing 2-guanidyl thiazole compounds by one-pot method | 西华大学 | 2023-11-17 | — | — | CN | disclosed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | ATP4A 996/4885ATP4B 1107/4885CSNK2A2 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.